Vir Biotechnology, a Phase 2 biotech developing immunologic therapies for infectious diseases, raised $143 million by offering 7.1 million shares at $20, the low end of the range of $20 to $22. Vir Biotechnology plans to list on the Nasdaq under the symbol VIR. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as lead managers on the deal.
